Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Yosinobu Onuma
  • ,
  • Patrick W Serruys
  • ,
  • John A Ormiston
  • ,
  • Evelyn Regar
  • ,
  • Mark Webster
  • ,
  • Leif Thuesen, Denmark
  • Dariusz Dudek
  • ,
  • Susan Veldhof
  • ,
  • Richard Rapoza
  • The Department of Cardiological Medicine B
Multimodality imaging of the first-in-man trial using a fully resorbable everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, CA, USA) demonstrated at two years the bioresorption of the device while preventing restenosis. Nevertheless, the long-term safety and efficacy of this novel therapy remain to be documented.
Original languageEnglish
Pages (from-to)447-53
Number of pages7
Publication statusPublished - 1 Sep 2010

See relations at Aarhus University Citationformats

ID: 34301050